Why Relay Therapeutics Stock Popped on Wednesday

Relay Therapeutics shares jumped nearly 8% after Phase 2 data for zovegalisib showed a 60% response rate at 12 weeks, with nearly all patients reporting symptomatic improvement and a positive safety/tolerability profile. Barclays raised its target to $27 from $21 and Citizens JMP lifted its target to $21 from $19, while both kept buy ratings. The upside was partly tempered by a planned secondary stock offering that could exceed $200 million.

Analysis

RLAY is getting a classic biotech re-rating setup: a genuinely better-than-feared mid-stage signal colliding with sell-side target resets that help validate the data for a broader base of investors. The immediate winners are existing holders and momentum accounts, but the larger second-order beneficiary may be the company itself if the capital raise is used to buy time and broaden the dataset rather than merely plug the balance sheet. In small/mid-cap biotech, a clean efficacy read plus visible financing often reduces the probability of a near-term discount catastrophe and can mechanically lower the implied cost of capital.

The market is likely underestimating the difference between “good Phase 2” and “commercially de-risking.” The real question is not whether the stock can keep working over days to weeks, but whether the program can sustain effect durability beyond the 12-week snapshot and whether the company can show dose/response and safety consistency in a larger, noisier cohort. If the next update merely confirms response rates without extending durability or broadening the label logic, today’s move will look more like a financing-relief rally than a durable platform rerating.

Consensus may also be too dismissive of dilution because the headline percentage is small versus market cap. In biotech, dilution matters less through EPS math and more through signaling: a raise immediately after data can cap upside if investors infer management wants to monetize strength before the next readout. That said, if the offering is used to fund the next catalyst window and avoid a tighter future financing, the smarter interpretation is that the company is extending runway into a more valuable binary event, which should support the multiple.

Key Decisions for Investors

• Stay long RLAY for 1-3 months, but size as a catalyst trade rather than a fundamental core position; use weakness toward the offering pricing as the better entry, since post-rally supply often creates a cleaner entry point than chasing the gap.
• Buy RLAY Jan/Apr call spreads instead of outright equity if liquidity allows; this captures further upside from validation of the Phase 2 signal while limiting dilution and data-reversal risk over the next 60-120 days.
• For relative value, pair long RLAY against a basket of less-differentiated clinical-stage biotech names with similar market caps and weaker cash runway; the trade benefits if the market continues rewarding clean efficacy plus funding visibility.
• Trim or hedge if the stock fails to hold the post-news range after the secondary is launched/price-settled, because that would indicate the move was driven by a temporary squeeze rather than durable institutional follow-through.
• Set a hard review point at the next clinical or financing disclosure: if durability, tolerability, and enrollment expansion are not clearly improving by then, reduce exposure before the market re-prices the program as a single-shot Phase 2 story.